GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer

FRÉDÉRIC SELLE & DOMINIQUE SPAETH et al.

Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice. Patients with ROC after at least one platinum-based regimen received 1.1 mg/m Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups. Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.
Authors
FRÉDÉRIC SELLE, PIERRE-ETIENNE HEUDEL, ANNE-CLAIRE HARDY-BESSARD, ASTRID POZET, JEROME MEUNIER, LAURENCE GLADIEFF, JEAN-PIERRE LOTZ, MAGALI PROVANSAL, PAULE AUGEREAU, DOMINIQUE BERTON, NATHALIE BONICHON-LAMICHHANE, HUBERT ORFEUVRE, PATRICIA PAUTIER, ELSA KALBACHER, YOUSEF TAZI, DOMINIQUE SPAETH